Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:3
  • preuzimanja u poslednjih 30 dana:1
članak: 2 od 2  
Back povratak na rezultate
Vojnosanitetski pregled
2005, vol. 62, br. 12, str. 879-885
jezik rada: engleski
vrsta rada: izvorni naučni članak
doi:10.2298/VSP0512879J


Ekopresija proteina p53 kod Barrettovog adenokarcinoma i adenokarcinoma kardije i antruma
aUniverzitet u Beogradu, Medicinski fakultet, Klinički centar Srbije
bUniverzitet u Beogradu, Institut za medicinska istraživanja, Beograd
cUniversity of Crete, Medical School, Heraclion, Crete, Greece

e-adresa: Ivangastro@beotel.yu

Sažetak

Uvod/Cilj. Veliki broj studija pokazao je da postoji visoka stopa mutacije gena p53 i/ili povećana ekspresija proteina p53 kod adenokarcinoma jednjaka i želuca, ali mali broj istraživanja je posvećen uporednim proučavanjima p53 na različitim lokalizacijama ovih tumora (gastroezofagogastrični spoj, Barrettov ezofagus i antrum). Zato je cilj ove studije bio proučavanje korelacije između kliničkopatoloških parametara i prekomerne ekspresije proteina p53 kod adenokarcinoma na navedenim lokalizacijama. Metode. Istraživanje je sprovedeno kod 66 bolesnika koji su operisani od Barrettovog adenokarcinoma (n = 10), adenokarcinoma kardije (n = 25, tip II adenokarcinoma ezofagogastričnog spoja) i adenokarcinoma antruma (n = 31). Imunohistohemijsko bojenje metodom alkaline phosphatase - antialkaline phosphatase (APAAP) u cilju dokazivanja preterane ekspresije proteina p53 sprovedeno je na tkivnim presecima hirurških uzoraka tumora fiksiranih u formalinu i ukalupljenih u parafin. Tumori „pozitivni“ na p53 bili su oni kod kojih je više od 5% tumorskih ćelija pokazalo nukleusno imunohistohemijsko bojenje. Rezultati. Između ispitivanih grupa bolesnika nije bilo razlika u distribuciji u odnosu na godine, pol, tip tumora po Laurenovoj klasifikaciji, kao i u odnosu na diferentovanost tumora. Međutim, postojala je značajna razlika u dubini tumorske invazije između Barrettovog adenokarcinoma i adenokarcinoma kardije u odnosu na adenokarcinom antruma. Naime, u momentu hirurške intervencije, stadijum tumorske bolesti bio je značajno veći kod Barrett-ovog adenokarcinoma i adenokarcinoma kardije u odnosu na adenokarcinom antruma. Prekomerna ekspresija proteina p53 nađena je kod 40% (4/10) slučajeva Barrettovog adenokarcinoma, 72% (18/25) slučajeva adenokarcinoma kardije, kao i kod 65% (20/31) bolesnika sa adenokarcinomom antruma. Nije bilo razlika u pogledu ekspresije proteina p53 između ispitanika različitih grupa u odnosu na ispitivane kliničko-patološke parametre: starost, pol, tip tumora, invazivnosti, zahvačenost limfnih nodusa i diferentovanost tumora. Zaključak. Između bolesnika sa Barrettovim adenokarcinomom, adenocarcinomom kardije i adenokarcinomom antruma nema razlika u prekomernoj ekspresiji proteina p53 u odnosu na starost, pol, tip tumora, invazivnosti, zahvačenost limfnih nodusa i diferentovanost tumora.

Ključne reči

Reference

Blot, W.J., Devesa, S.S., Kneller, R.W., Fraumeni, J.F. (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA, 265(10): 1287-9
Casson, A.G., Mukhopadhyay, T., Cleary, K.R., Ro, J.Y., Levin, B., Roth, J.A. (1991) p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res, 51(16): 4495-9
Craanen, M.E., Dekker, W., Blok, P., Ferwerda, J., Tytgat, G.N. (1992) Time trends in gastric carcinoma: Changing patterns of type and location. Am J Gastroenterol, 87(5): 572-9
Flejou, J.F., Gratio, V., Muzeau, F., Hamelin, R. (1999) p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. Mol Pathol, 52(5): 263-8
Flejou, J.F., Paraf, F., Potet, F., Muzeau, F., Fekete, F., Henin, D. (1994) p53 protein expression in Barrett's adenocarcinoma: A frequent event with no prognostic significance. Histopathology, 24(5): 487-9
Gabbert, H.E., Muller, W., Schneiders, A., Meier, S., Hommel, G. (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer, 76(5): 720-6
Gleeson, C.M., Sloan, J.M., McManus, D.T., Maxwell, P., Arthur, K., McGuigan, J.A., Ritchie, A.J., Russell, S.E. (1998) Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer, 77(2): 277-86
Haggitt, R.C. (1994) Barrett's esophagus, dysplasia and adenocarcinoma. Hum Pathol, 25:982-93
Hansson, L.E., Engstrand, L., Nyren, O., Evans, D.J., Lindgren, A., Bergstrom, R., Andersson, B., Athlin, L., Bendtsen, O., Tracz, P. (1993) Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma. Gastroenterology, 105(4): 1098-103
Harrison, L.E., Karpeh, M.S., Brennan, M.F. (1997) Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. Ann Surg, 225(6): 678-83; di
Hickman, E.S., Moroni, M., Helin, K. (2002) The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev, 12(1): 60-6
Ireland, A.P., Clark, G.W., DeMeester, T.R. (1997) Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg, 225(1): 17-30
Jankowski, J.A., Wright, N.A., Meltzer, S.J., Triadafilopoulos, G., Geboes, K., Casson, A.G., Kerr, D., Young, L.S. (1999) Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol, 154(4): 965-73
Johnson, H., Belluco, C., Masood, S., Abou-Azama, A.M., Kahn, L., Wise, L. (1993) The value of flow cytometric analysis in patients with gastric cancer. Arch Surg, 128(3): 314-7
Kalish, R.J., Clancy, P.E., Orringer, M.B., Appelman, H.D. (1984) Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia. Gastroenterology, 86(3): 461-7
Kauer, W.K., Burdiles, P., Ireland, A.P., Clark, G.W., Peters, J.H., Bremner, C.G., DeMeester, T.R. (1995) Does duodenal juice reflux into the esophagus of patients with complicated GERD? Evaluation of a fiberoptic sensor for bilirubin. Am J Surg, 169(1): 98-103; di
Lauren, P. (1965) The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand, 64: 31-49
Levine, A.J., Momand, J., Finlay, C.A. (1991) The p53 tumour suppressor gene. Nature, 351(6326): 453-6
Meyer-Rosberg, K., Scott, D.R., Rex, D., Melchers, K., Sachs, G. (1996) The effect of environmental pH on the proton motive force of Helicobacter pylori. Gastroenterology, 111(4): 886-900
Monig, S.P., Eidt, S., Zirbes, T.K., Stippel, D., Baldus, S.E., Pichlmaier, H. (1997) p53 expression in gastric cancer: Clinicopathological correlation and prognostic significance. Dig Dis Sci, 42(12): 2463-7
Muzeau, F., Flejou, J.F., Belghiti, J., Thomas, G., Hamelin, R. (1997) Infrequent microsatellite instability in oesophageal cancers. Br J Cancer, 75(9): 1336-9
Oberg, S., Peters, J.H., DeMeester, T.R., Chandrasoma, P., Hagen, J.A., Ireland, A.P., Ritter, M.P., Mason, R.J., Crookes, P., Bremner, C.G. (1997) Inflammation and specialized intestinal metaplasia of cardiac mucosa is a manifestation of gastroesophageal reflux disease. Ann Surg, 226(4): 522-30; di
Powell, J., McConkey, C.C. (1992) The rising trend in oesophageal adenocarcinoma and gastric cardia. Eur J Cancer Prev, 1(3): 265-9
Rajnakova, A., Moochhala, S., Goh, P.M., Ngoi, S. (2001) Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett, 172(2): 177-85
Ranzani, G.N., Luinetti, O., Padovan, L.S., Calistri, D., Renault, B., Burrel, M., Amadori, D., Fiocca, R., Solcia, E. (1995) p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev, 4(3): 223-31
Reid, B.J., Prevo, L.J., Galipeau, P.C., Sanchez, C.A., Longton, G., Levine, D.S., Blount, P.L., Rabinovitch, P.S. (2001) Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol, 96(10): 2839-48
Rohde, H., Bauer, P., Stutzer, H., Heitmann, K., Gebbensleben, B. (1991) Proximal compared with distal adenocarcinoma of the stomach: Differences and consequences. German Gastric Cancer TNM Study Group. Br J Surg, 78(10): 1242-8
Shun, C.T., Wu, M.S., Lin, J.T., Chen, S.Y., Wang, H.P., Lee, W.J., Wang, T.H., Chuang, S.M. (1997) Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology, 44(14): 604-9
Siewert, J.R., Stein, H.J. (1998) Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg, 85(11): 1457-9
Souza, R.F., Meltzer, S.J. (1997) The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. Gastroenterol Clin North Am, 26(3): 583-97
Spechler, S.J., Goyal, R.K. (1996) The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology, 110(2): 614-21
Tahara, E., Semba, S., Tahara, H. (1996) Molecular biological observations in gastric cancer. Semin Oncol, 23(3): 307-15
Toner, P.G., Cameron, C.H.S. (1995) The gastric mucosa. u: Whitehead R. [ur.] Gastrointestinal and oesophageal pathology, Edinburgh, itd: Churchill-Livingstone, 2nd edition., 15-32
Weston, A.P., Krmpotich, P.T., Cherian, R., Dixon, A., Topalosvki, M. (1997) Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: Comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol, 92(3): 407-13
Wu, T.T., Watanabe, T., Heitmiller, R., Zahurak, M., Forastiere, A.A., Hamilton, S.R. (1998) Genetic alterations in Barrett esophagus and adenocarcinomas of the esophagus and esophagogastric junction region. Am J Pathol, 153(1): 287-94